CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma...
Phase 2
Washington, District of Columbia, United States and 2 other locations
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Fairfax, Virginia, United States and 113 other locations
(nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma...
Phase 2
Fairfax, Virginia, United States and 5 other locations
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by...
Phase 2
Baltimore, Maryland, United States and 1 other location
This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD)...
Phase 1
Washington, District of Columbia, United States
The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously t...
Phase 2
Baltimore, Maryland, United States
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Baltimore, Maryland, United States and 6 other locations
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker pat...
Phase 2
Fairfax, Virginia, United States and 18 other locations
combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...
Phase 1, Phase 2
Washington, District of Columbia, United States and 26 other locations
will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, ...
Phase 1, Phase 2
Fairfax, Virginia, United States and 5 other locations
Clinical trials
Research sites
Resources
Legal